| Open |
S1703 |
Disease Monitoring Study |
7/16/2018 |
|
46% |
|
|
| Open |
S1905 |
PI/II OBI-3424 for R/R T-ALL/T-LBL |
8/17/2020 |
|
23% |
|
|
| Open |
S1706 |
Phase II Rando, Double Blind Placebo/Veliparib + RT for Inflammatory Breast |
9/12/2018 |
|
52% |
|
|
| Open |
S1802 |
PhIII Rando SST v. SST+Surgery or Radiation for Met Prostate Cancer |
9/17/2018 |
|
63% |
|
|
| Open |
LUNGMAP |
LUNGMAP Screening Protocol for NSCLC |
1/28/2019 |
|
|
|
|
| Closed |
S1900A |
LUNGMAP S1900A: LOH HIGH and/or BRCA 1/2 mutation - Rucaparib |
1/29/2019 |
|
73% |
|
|
| Closed |
S1714 |
CIPN |
3/1/2019 |
|
100% |
|
|
| Closed |
S1806 |
Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer. |
4/19/2019 |
|
100% |
|
|
| Closed |
S1916 |
Digital Medicine for Opioid Pain Control |
6/11/2019 |
|
3% |
|
|
| Open |
S1922 |
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma |
12/16/2019 |
|
34% |
|
|
| Open |
S1827 |
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) |
1/10/2020 |
|
33% |
|
|
| Closed |
S1900B |
LUNGMAP S1900B: RET Fustion Positive - LOXO-292 |
2/10/2020 |
|
5% |
|
|
| Open |
S1914 |
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC |
3/25/2020 |
|
75% |
|
|
| Open |
S1823 |
miRNA 371 Study in Germ Cell Tumors |
6/1/2020 |
|
100% |
|
|
| Open |
S1933 |
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status |
6/15/2020 |
|
79% |
|
|
| Open |
SLA01 |
IMMUNE CHECKPOINTS IN GASTRIC CANCER FROM LATIN AMERICAN COUNTRIES |
|
|
0% |
|
|
| Open |
S1904 |
Decision Support Tool |
9/1/2020 |
|
97% |
|
|
| Open |
S2000 |
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases |
9/23/2020 |
|
94% |
|
|
| Open |
S1931 |
PROBE trial |
11/16/2020 |
|
29% |
|
|
| Open |
S2001 |
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects |
12/4/2020 |
|
57% |
|
|
